ZYME Company Profile and Key Details

Q: Who are the executives of ZYME?

Dr. Ali Tehrani Ph.D.AdvisorDr. Ryan Dercho Ph.D.Senior Director of Corporation AffairsNina Weisser Ph.D.Director of Multispecific Antibody TherapeuticsDr. Paul Moore Ph.D.Chief Scientific OfficerDr. Christopher Astle Ph.D.Senior Vice President & Chief Financial OfficerMr. Neil A. Klompas C.A., CPA, CA, CPAPres & Chief Operating OfficerDr. Neil Josephson M.D.Chief Medical OfficerJack W. SpinksAssociate Director of Investor RelationsMr. Kenneth H. Galbraith C.A.Chief Executive Officer & ChairmanDr. David Poon Ph.D.Vice President of Bus. Devel. and Alliance ManagementDiana PapoveSenior Mang. of Corporation CommunicationsDr. Jeffrey Smith M.D.Senior Vice President of Early-Stage Devel.Mr. Mark HollywoodExecutive Vice President and Head of Technical & Manufacturing OperationsMr. Daniel Dex J.D., Ph.D.Senior Vice President, Corporation Sec. & Gen. CounselMs. Laura O'ConnorExecutive Director & Head of Global HRMs. Bijal Desai M.B.A.Executive Director of Corporation Fin., FP&A & ProcurementMr. Neil A. Klompas C.A., C.P.A., CA, CPAPres & Chief Operating Officer

NASDAQ : ZYME

Zymeworks

$24.04

-1.06-4.22%

Open: 4:00 PM

60.77

BESG ScoreESG Rating

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

Zymeworks Inc. (ZYME) stock declined over -4.22%, trading at $24.04 on NASDAQ, down from the previous close of $25.10. The stock opened at $25.04, fluctuating between $24.02 and $25.12 in the recent session.

Stock Snapshot

25.1

Prev. Close

1.77B

Market Cap

24.02

Day Low

-17.55

P/E Ratio

-1.37

EPS (TTM)

-1.73

Cash Flow per Share

25.04

Open

73.57M

Number of Shares

25.115

Day High

97.04%

Free Float in %

6.56

Book Value

458.16K

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Jun 05, 2026	25.04	25.12	24.02	24.04	464.84K
Jun 04, 2026	24.64	25.30	24.34	25.10	467.17K
Jun 03, 2026	24.32	24.43	23.94	24.35	521.46K
Jun 01, 2026	25.01	25.01	23.93	24.54	1.91M
May 29, 2026	25.32	25.62	24.96	25.13	585.45K
May 28, 2026	24.61	25.54	24.48	25.48	389.92K
May 27, 2026	25.40	26.19	24.78	24.79	509.44K
May 26, 2026	25.60	26.00	25.15	25.40	1M
May 22, 2026	25.20	25.68	24.94	25.61	477.95K
May 21, 2026	24.42	25.36	24.37	25.11	618.62K
May 20, 2026	24.40	25.20	24.27	24.84	542.86K
May 19, 2026	24.19	24.55	23.87	24.40	615.32K
May 18, 2026	23.93	24.70	23.88	24.43	750.24K
May 15, 2026	24.50	25.34	23.63	23.93	640.8K
May 14, 2026	24.75	24.75	23.50	23.96	557.48K
May 13, 2026	23.88	24.94	23.75	24.57	646.78K
May 12, 2026	24.15	24.58	23.66	23.90	717.86K
May 11, 2026	23.76	24.99	23.72	24.03	871.31K
May 08, 2026	26.21	26.21	23.39	23.89	1.45M
May 07, 2026	27.67	27.96	26.25	26.60	427.4K

Contact Details

Middletown, BC V5T 1G4

Canada

https://www.zymeworks.com 160 467 81388

About Company

Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a novel bispecific antibody that is in Phase 1 and Phase 2 clinical trials for the treatment of biliary tract, gastroesophageal adenocarcinomas, breast, and colorectal cancer; and ZW49, a biparatopic anti-human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate that is in Phase 1 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. The company has strategic partnerships with Merck Sharp & Dohme Research Ltd.; Eli Lilly and Company; Bristol-Myers Squibb company; GlaxoSmithKline Intellectual Property Development Ltd.; Daiichi Sankyo Co., Ltd.; Janssen Biotech, Inc.; BeiGene, Ltd.; and Exelixis, Inc. It also has licensing and research collaboration with LEO Pharma A/S to research, develop, and commercialize bispecific antibodies; and Iconic Therapeutics, Inc. Zymeworks Inc. was incorporated in 2003 and is headquartered in Vancouver, Canada.

Stock Peers

ARGX

49.05+5.82%

argenx SE$891.32 REGN

6.72+1.07%

Regeneron Pharmaceuticals, Inc.$635.45 UTHR

2.18+0.40%

United Therapeutics Corporation$549.87 MDGL

-5.85-1.19%

Madrigal Pharmaceuticals, Inc.$486.98 VRTX

5.09+1.15%

Vertex Pharmaceuticals Incorporated$446.83 KRTX

0.09+0.03%

Karuna Therapeutics, Inc.$329.83 ALNY

-0.59-0.19%

Alnylam Pharmaceuticals, Inc.$303.05 KRYS

-6.79-2.21%

Krystal Biotech, Inc.$301.00 PRAX

-10.75-4.06%

Praxis Precision Medicines, Inc.$254.00 JAZZ

-1.49-0.62%

Jazz Pharmaceuticals plc$238.57

Frequently Asked Questions

What is the current Zymeworks Inc. (ZYME) stock price?

Zymeworks Inc. (NASDAQ: ZYME) stock price is $24.04 in the last trading session. During the trading session, ZYME stock reached the peak price of $25.12 while $24.02 was the lowest point it dropped to. The percentage change in ZYME stock occurred in the recent session was -4.22% while the dollar amount for the price change in ZYME stock was - $1.06.

ZYME's industry and sector of operation?

The NASDAQ listed ZYME is part of Biotechnology industry that operates in the broader Healthcare sector. Zymeworks Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of ZYME?

Dr. Ali Tehrani Ph.D.
Advisor
Dr. Ryan Dercho Ph.D.
Senior Director of Corporation Affairs
Nina Weisser Ph.D.
Director of Multispecific Antibody Therapeutics
Dr. Paul Moore Ph.D.
Chief Scientific Officer
Dr. Christopher Astle Ph.D.
Senior Vice President & Chief Financial Officer
Mr. Neil A. Klompas C.A., CPA, CA, CPA
Pres & Chief Operating Officer
Dr. Neil Josephson M.D.
Chief Medical Officer
Jack W. Spinks
Associate Director of Investor Relations
Mr. Kenneth H. Galbraith C.A.
Chief Executive Officer & Chairman
Dr. David Poon Ph.D.
Vice President of Bus. Devel. and Alliance Management
Diana Papove
Senior Mang. of Corporation Communications
Dr. Jeffrey Smith M.D.
Senior Vice President of Early-Stage Devel.
Mr. Mark Hollywood
Executive Vice President and Head of Technical & Manufacturing Operations
Mr. Daniel Dex J.D., Ph.D.
Senior Vice President, Corporation Sec. & Gen. Counsel
Ms. Laura O'Connor
Executive Director & Head of Global HR
Ms. Bijal Desai M.B.A.
Executive Director of Corporation Fin., FP&A & Procurement
Mr. Neil A. Klompas C.A., C.P.A., CA, CPA
Pres & Chief Operating Officer

How ZYME did perform over past 52-week?

ZYME's closing price is 108.86% higher than its 52-week low of $11.51 where as its distance from 52-week high of $29.75 is -19.19%.

How many employees does ZYME have?

Number of ZYME employees currently stands at 299.

Link for ZYME official website?

Official Website of ZYME is: https://www.zymeworks.com

How do I contact ZYME?

ZYME could be contacted at phone 160 467 81388 and can also be accessed through its website. ZYME operates from 114 East 4th Avenue, Middletown, BC V5T 1G4, Canada.

How many shares of ZYME are traded daily?

ZYME stock volume for the day was 458.16K shares. The average number of ZYME shares traded daily for last 3 months was 686.91K.

What is the market cap of ZYME currently?

The market value of ZYME currently stands at $1.77B with its latest stock price at $24.04 and 73.57M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	299
Beta	1.28
Sales or Revenue	$76.01M
5Y Sales Change%	-0.396%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Biotechnology

Employees	299
Beta	1.28
Sales or Revenue	$76.01M
5Y Sales Change%	-0.396%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Biotechnology

ZYME Company Profile and Key Details

Zymeworks

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Frequently Asked Questions

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Technical Performance

Financial & Profitability Overview

Quarterly Financial Highlights

Dividend & Fair Value

Earnings & Analyst Outlook

Company Overview

Valuation Metrics

Key Takeaways

Price Forecast & Outlook